IVF Unit, Department of Obstetrics and Gynecology, Shamir Medical Center, Zerifin, Israel.
Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Hum Reprod. 2022 May 3;37(5):947-953. doi: 10.1093/humrep/deac043.
Does prior severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in women undergoing fertility treatments affect the outcomes of fresh ART cycles?
SARS-CoV-2 infection does not affect fresh ART treatment outcomes, except for a possible long-term negative effect on oocyte yield (>180 days postinfection).
A single previous study suggested no evidence that a history of asymptomatic or mild SARS-CoV-2 infection in females caused impairment of fresh ART treatment outcomes.
STUDY DESIGN, SIZE, DURATION: Retrospective cohort study, including all SARS-CoV-2 infected women who underwent fresh ART cycles within a year from infection (the first cycle postinfection), between October 2020 and June 2021, matched to non-diagnosed controls.
PARTICIPANTS/MATERIALS, SETTING, METHODS: Patients from two large IVF units in Israel who were infected with SARS-CoV-2 and later underwent fresh ART cycles were matched by age to non-diagnosed, non-vaccinated controls. Demographics, cycle characteristics and cycle outcomes, including oocyte yield, maturation rate, fertilization rate, number of frozen embryos per cycle and clinical pregnancy rates, were compared between groups.
One hundred and twenty-one infected patients and 121 controls who underwent fresh ART cycles were included. Oocyte yield (12.50 versus 11.29; P = 0.169) and mature oocyte rate (78% versus 82%; P = 0.144) in all fresh cycles were similar between groups, as were fertilization rates, number of frozen embryos per cycle and clinical pregnancy rates (43% versus 40%; P = 0.737) in fresh cycles with an embryo transfer. In a logistic regression model, SARS-CoV-2 infection more than 180 days prior to retrieval had a negative effect on oocyte yield (P = 0.018, Slope = -4.08, 95% CI -7.41 to -0.75), although the sample size was small.
LIMITATIONS, REASONS FOR CAUTION: A retrospective study with data that was not uniformly generated under a study protocol, no antibody testing for the control group.
The study findings suggest that SARS-CoV-2 infection does not affect treatment outcomes, including oocyte yield, fertilization and maturation rate, number of good quality embryos and clinical pregnancy rates, in fresh ART cycles, except for a possible long-term negative effect on oocyte yield when retrieval occurs >180 days post-SARS-CoV-2 infection. Further studies are warranted to support these findings.
STUDY FUNDING/COMPETING INTEREST(S): None.
0010-21-HMC, 0094-21-ASF.
女性在接受生育治疗时先前是否患有严重急性呼吸系统综合征冠状病毒 2 型（SARS-CoV-2）感染会影响新鲜的辅助生殖技术（ART）周期的结果吗？
SARS-CoV-2 感染不会影响新鲜的 ART 治疗结果，除非感染后 180 天以上对卵母细胞产量有潜在的长期负面影响。
仅有一项先前的研究表明，女性无症状或轻度 SARS-CoV-2 感染史不会损害新鲜的 ART 治疗结果。
研究设计、规模、持续时间：回顾性队列研究，纳入 2020 年 10 月至 2021 年 6 月期间一年内因 SARS-CoV-2 感染而接受新鲜 ART 周期（感染后第一周期）的所有 SARS-CoV-2 感染女性，与未诊断的对照组相匹配。
参与者/材料、地点、方法：以色列两家大型试管婴儿单位的患者感染 SARS-CoV-2 后接受新鲜的 ART 周期，通过年龄与未诊断、未接种疫苗的对照组相匹配。比较两组间的人口统计学、周期特征和周期结果，包括卵母细胞产量、成熟率、受精率、每个周期的冷冻胚胎数量和临床妊娠率。
共纳入 121 例感染患者和 121 例接受新鲜 ART 周期的对照组。所有新鲜周期的卵母细胞产量（12.50 与 11.29；P=0.169）和成熟卵母细胞率（78%与 82%；P=0.144）相似，新鲜周期的受精率、每个周期的冷冻胚胎数量和临床妊娠率（43%与 40%；P=0.737）在有胚胎移植的新鲜周期中也相似。在逻辑回归模型中，与取卵前 180 天以上的 SARS-CoV-2 感染相比，取卵前 180 天以上的 SARS-CoV-2 感染对卵母细胞产量有负面影响（P=0.018，斜率=-4.08，95%CI-7.41 至-0.75），尽管样本量较小。
局限性、谨慎的原因：这是一项回顾性研究，数据不是根据研究方案统一生成的，对照组没有抗体检测。
研究结果表明，SARS-CoV-2 感染不会影响新鲜的 ART 周期的治疗结果，包括卵母细胞产量、受精和成熟率、高质量胚胎数量和临床妊娠率，除非感染后 180 天以上取卵对卵母细胞产量有潜在的长期负面影响。需要进一步的研究来支持这些发现。
研究经费/利益冲突：无。
0010-21-HMC，0094-21-ASF。
